APO Research
Talk to an analyst

APO RESEARCH · REPORT

NK-1 Receptor Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global NK-1 Receptor Antagonists Market Outlook and Growth Opportunities 2026

29 December 2025203 pages

Choose your research edition.

Industry ResearchNK-1 Receptor Antagonists Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal NK-1 Receptor Antagonists Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal NK-1 Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NK-1 Receptor Antagonists Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal NK-1 Receptor Antagonists Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global NK-1 Receptor Antagonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for NK-1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for NK-1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NK-1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the NK-1 Receptor Antagonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the NK-1 Receptor Antagonists market include Dr. Reddy's Laboratories, Eugia Pharma, Fresenius Kabi, Glenmark, Helsinn Healthcare, Heron Therapeutics, Lupin, MSN and Mylan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global NK-1 Receptor Antagonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of NK-1 Receptor Antagonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents NK-1 Receptor Antagonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the NK-1 Receptor Antagonists market size, projected growth trends, production technologies, key applications, and end-use industries.

NK-1 Receptor Antagonists Segment by Company

Dr. Reddy's Laboratories

Eugia Pharma

Fresenius Kabi

Glenmark

Helsinn Healthcare

Heron Therapeutics

Lupin

MSN

Mylan

Steriscience

TerSera Therapeutics

Teva

Torrent Pharmaceuticals

Beijing Sihuan Pharmaceutical

Hansoh Pharma

Merck

Qilu Pharmaceutical

Sandoz

Yichang Humanwell Pharmaceutical

Chia Tai Tianqing Pharmaceutical

NK-1 Receptor Antagonists Segment by Type

Netupitant

Maropitant

Rolapitant

Fosaprepitant

Aprepitant

Other

NK-1 Receptor Antagonists Segment by Application

Chemotherapy-induced Nausea and Vomiting (CINV)

Postoperative Nausea and Vomiting (PONV)

Other

NK-1 Receptor Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global NK-1 Receptor Antagonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions NK-1 Receptor Antagonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify NK-1 Receptor Antagonists significant trends, drivers, influence factors in global and regions.

6. To analyze NK-1 Receptor Antagonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK-1 Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NK-1 Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK-1 Receptor Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the NK-1 Receptor Antagonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NK-1 Receptor Antagonists industry.

Chapter 3: Detailed analysis of NK-1 Receptor Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of NK-1 Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of NK-1 Receptor Antagonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. NK-1 Receptor Antagonists Industry Trends Table 2. NK-1 Receptor Antagonists Industry Drivers Table 3. NK-1 Receptor Antagonists Industry Opportunities and Challenges Table 4. NK-1 Receptor Antagonists Industry Restraints Table 5. Global NK-1 Receptor Antagonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global NK-1 Receptor Antagonists Revenue Share by Company (2021-2026) Table 7. Global NK-1 Receptor Antagonists Sales Volume by Company (K Units) & (2021-2026) Table 8. Global NK-1 Receptor Antagonists Sales Volume Share by Company (2021-2026) Table 9. Global NK-1 Receptor Antagonists Average Price (US$/Unit) of Company (2021-2026) Table 10. Global NK-1 Receptor Antagonists Company Ranking, (2024-2026) & (USD Million) Table 11. Global NK-1 Receptor Antagonists Key Company Manufacturing Base & Headquarters Table 12. Global NK-1 Receptor Antagonists Company, Product Type & Application Table 13. Global NK-1 Receptor Antagonists Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global NK-1 Receptor Antagonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Netupitant Table 18. Significant Companies of Maropitant Table 19. Significant Companies of Rolapitant Table 20. Significant Companies of Fosaprepitant Table 21. Significant Companies of Aprepitant Table 22. Significant Companies of Other Table 23. Global NK-1 Receptor Antagonists Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global NK-1 Receptor Antagonists Sales Volume by Type (2021-2026) & (K Units) Table 25. Global NK-1 Receptor Antagonists Sales Volume by Type (2027-2032) & (K Units) Table 26. Global NK-1 Receptor Antagonists Sales Volume Share by Type (2021-2026) Table 27. Global NK-1 Receptor Antagonists Sales Volume Share by Type (2027-2032) Table 28. Global NK-1 Receptor Antagonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global NK-1 Receptor Antagonists Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global NK-1 Receptor Antagonists Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global NK-1 Receptor Antagonists Sales Value Share by Type (2021-2026) Table 32. Global NK-1 Receptor Antagonists Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Chemotherapy-induced Nausea and Vomiting (CINV) Table 34. Significant Companies of Postoperative Nausea and Vomiting (PONV) Table 35. Significant Companies of Other Table 36. Global NK-1 Receptor Antagonists Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global NK-1 Receptor Antagonists Sales Volume by Application (2021-2026) & (K Units) Table 38. Global NK-1 Receptor Antagonists Sales Volume by Application (2027-2032) & (K Units) Table 39. Global NK-1 Receptor Antagonists Sales Volume Share by Application (2021-2026) Table 40. Global NK-1 Receptor Antagonists Sales Volume Share by Application (2027-2032) Table 41. Global NK-1 Receptor Antagonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global NK-1 Receptor Antagonists Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global NK-1 Receptor Antagonists Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global NK-1 Receptor Antagonists Sales Value Share by Application (2021-2026) Table 45. Global NK-1 Receptor Antagonists Sales Value Share by Application (2027-2032) Table 46. Global NK-1 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global NK-1 Receptor Antagonists Sales by Region (2021-2026) & (K Units) Table 48. Global NK-1 Receptor Antagonists Sales Market Share by Region (2021-2026) Table 49. Global NK-1 Receptor Antagonists Sales by Region (2027-2032) & (K Units) Table 50. Global NK-1 Receptor Antagonists Sales Market Share by Region (2027-2032) Table 51. Global NK-1 Receptor Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global NK-1 Receptor Antagonists Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global NK-1 Receptor Antagonists Sales Value Share by Region (2021-2026) Table 54. Global NK-1 Receptor Antagonists Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global NK-1 Receptor Antagonists Sales Value Share by Region (2027-2032) Table 56. Global NK-1 Receptor Antagonists Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global NK-1 Receptor Antagonists Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global NK-1 Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global NK-1 Receptor Antagonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global NK-1 Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 61. Global NK-1 Receptor Antagonists Sales Market Share by Country (2021-2026) Table 62. Global NK-1 Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 63. Global NK-1 Receptor Antagonists Sales Market Share by Country (2027-2032) Table 64. Global NK-1 Receptor Antagonists Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global NK-1 Receptor Antagonists Sales Value Market Share by Country (2021-2026) Table 66. Global NK-1 Receptor Antagonists Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global NK-1 Receptor Antagonists Sales Value Market Share by Country (2027-2032) Table 68. Dr. Reddy's Laboratories Company Information Table 69. Dr. Reddy's Laboratories Business Overview Table 70. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolio Table 72. Dr. Reddy's Laboratories Recent Development Table 73. Eugia Pharma Company Information Table 74. Eugia Pharma Business Overview Table 75. Eugia Pharma NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Eugia Pharma NK-1 Receptor Antagonists Product Portfolio Table 77. Eugia Pharma Recent Development Table 78. Fresenius Kabi Company Information Table 79. Fresenius Kabi Business Overview Table 80. Fresenius Kabi NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Fresenius Kabi NK-1 Receptor Antagonists Product Portfolio Table 82. Fresenius Kabi Recent Development Table 83. Glenmark Company Information Table 84. Glenmark Business Overview Table 85. Glenmark NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Glenmark NK-1 Receptor Antagonists Product Portfolio Table 87. Glenmark Recent Development Table 88. Helsinn Healthcare Company Information Table 89. Helsinn Healthcare Business Overview Table 90. Helsinn Healthcare NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolio Table 92. Helsinn Healthcare Recent Development Table 93. Heron Therapeutics Company Information Table 94. Heron Therapeutics Business Overview Table 95. Heron Therapeutics NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Heron Therapeutics NK-1 Receptor Antagonists Product Portfolio Table 97. Heron Therapeutics Recent Development Table 98. Lupin Company Information Table 99. Lupin Business Overview Table 100. Lupin NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Lupin NK-1 Receptor Antagonists Product Portfolio Table 102. Lupin Recent Development Table 103. MSN Company Information Table 104. MSN Business Overview Table 105. MSN NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. MSN NK-1 Receptor Antagonists Product Portfolio Table 107. MSN Recent Development Table 108. Mylan Company Information Table 109. Mylan Business Overview Table 110. Mylan NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Mylan NK-1 Receptor Antagonists Product Portfolio Table 112. Mylan Recent Development Table 113. Steriscience Company Information Table 114. Steriscience Business Overview Table 115. Steriscience NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Steriscience NK-1 Receptor Antagonists Product Portfolio Table 117. Steriscience Recent Development Table 118. TerSera Therapeutics Company Information Table 119. TerSera Therapeutics Business Overview Table 120. TerSera Therapeutics NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolio Table 122. TerSera Therapeutics Recent Development Table 123. Teva Company Information Table 124. Teva Business Overview Table 125. Teva NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Teva NK-1 Receptor Antagonists Product Portfolio Table 127. Teva Recent Development Table 128. Torrent Pharmaceuticals Company Information Table 129. Torrent Pharmaceuticals Business Overview Table 130. Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolio Table 132. Torrent Pharmaceuticals Recent Development Table 133. Beijing Sihuan Pharmaceutical Company Information Table 134. Beijing Sihuan Pharmaceutical Business Overview Table 135. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 137. Beijing Sihuan Pharmaceutical Recent Development Table 138. Hansoh Pharma Company Information Table 139. Hansoh Pharma Business Overview Table 140. Hansoh Pharma NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Hansoh Pharma NK-1 Receptor Antagonists Product Portfolio Table 142. Hansoh Pharma Recent Development Table 143. Merck Company Information Table 144. Merck Business Overview Table 145. Merck NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Merck NK-1 Receptor Antagonists Product Portfolio Table 147. Merck Recent Development Table 148. Qilu Pharmaceutical Company Information Table 149. Qilu Pharmaceutical Business Overview Table 150. Qilu Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 152. Qilu Pharmaceutical Recent Development Table 153. Sandoz Company Information Table 154. Sandoz Business Overview Table 155. Sandoz NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Sandoz NK-1 Receptor Antagonists Product Portfolio Table 157. Sandoz Recent Development Table 158. Yichang Humanwell Pharmaceutical Company Information Table 159. Yichang Humanwell Pharmaceutical Business Overview Table 160. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 162. Yichang Humanwell Pharmaceutical Recent Development Table 163. Chia Tai Tianqing Pharmaceutical Company Information Table 164. Chia Tai Tianqing Pharmaceutical Business Overview Table 165. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolio Table 167. Chia Tai Tianqing Pharmaceutical Recent Development Table 168. Key Raw Materials Table 169. Raw Materials Key Suppliers Table 170. NK-1 Receptor Antagonists Distributors List Table 171. NK-1 Receptor Antagonists Customers List Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. NK-1 Receptor Antagonists Product Image Figure 2. Global NK-1 Receptor Antagonists Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NK-1 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 4. Global NK-1 Receptor Antagonists Sales (2021-2032) & (K Units) Figure 5. Global NK-1 Receptor Antagonists Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global NK-1 Receptor Antagonists Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Netupitant Image Figure 10. Maropitant Image Figure 11. Rolapitant Image Figure 12. Fosaprepitant Image Figure 13. Aprepitant Image Figure 14. Other Image Figure 15. Global NK-1 Receptor Antagonists Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global NK-1 Receptor Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global NK-1 Receptor Antagonists Sales Volume Share by Type (2021-2032) Figure 18. Global NK-1 Receptor Antagonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global NK-1 Receptor Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global NK-1 Receptor Antagonists Sales Value Share by Type (2021-2032) Figure 21. Chemotherapy-induced Nausea and Vomiting (CINV) Image Figure 22. Postoperative Nausea and Vomiting (PONV) Image Figure 23. Other Image Figure 24. Global NK-1 Receptor Antagonists Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global NK-1 Receptor Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global NK-1 Receptor Antagonists Sales Volume Share by Application (2021-2032) Figure 27. Global NK-1 Receptor Antagonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global NK-1 Receptor Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global NK-1 Receptor Antagonists Sales Value Share by Application (2021-2032) Figure 30. Global NK-1 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global NK-1 Receptor Antagonists Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global NK-1 Receptor Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global NK-1 Receptor Antagonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America NK-1 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 35. North America NK-1 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe NK-1 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 37. Europe NK-1 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific NK-1 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific NK-1 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America NK-1 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 41. South America NK-1 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa NK-1 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa NK-1 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. NK-1 Receptor Antagonists Value Chain Figure 129. Manufacturing Cost Structure Figure 130. NK-1 Receptor Antagonists Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Netupitant
  • Maropitant
  • Rolapitant
  • Fosaprepitant
  • Aprepitant
  • Other
Applications
  • Chemotherapy-induced Nausea and Vomiting (CINV)
  • Postoperative Nausea and Vomiting (PONV)
  • Other
Companies covered
  • Dr. Reddy's Laboratories
  • Eugia Pharma
  • Fresenius Kabi
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • Lupin
  • MSN
  • Mylan
  • Steriscience
  • TerSera Therapeutics
  • Teva
  • Torrent Pharmaceuticals
  • Beijing Sihuan Pharmaceutical
  • Hansoh Pharma
  • Merck
  • Qilu Pharmaceutical
  • Sandoz
  • Yichang Humanwell Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global NK-1 Receptor Antagonists Sales Value (2021-2032)
  4. 1.2.2 Global NK-1 Receptor Antagonists Sales Volume (2021-2032)
  5. 1.2.3 Global NK-1 Receptor Antagonists Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 NK-1 Receptor Antagonists Market Dynamics
  1. 2.1 NK-1 Receptor Antagonists Industry Trends
  2. 2.2 NK-1 Receptor Antagonists Industry Drivers
  3. 2.3 NK-1 Receptor Antagonists Industry Opportunities and Challenges
  4. 2.4 NK-1 Receptor Antagonists Industry Restraints
3 NK-1 Receptor Antagonists Market by Company
  1. 3.1 Global NK-1 Receptor Antagonists Company Revenue Ranking in 2025
  2. 3.2 Global NK-1 Receptor Antagonists Revenue by Company (2021-2026)
  3. 3.3 Global NK-1 Receptor Antagonists Sales Volume by Company (2021-2026)
  4. 3.4 Global NK-1 Receptor Antagonists Average Price by Company (2021-2026)
  5. 3.5 Global NK-1 Receptor Antagonists Company Ranking (2024-2026)
  6. 3.6 Global NK-1 Receptor Antagonists Company Manufacturing Base and Headquarters
  7. 3.7 Global NK-1 Receptor Antagonists Company Product Type and Application
  8. 3.8 Global NK-1 Receptor Antagonists Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global NK-1 Receptor Antagonists Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 NK-1 Receptor Antagonists Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 NK-1 Receptor Antagonists Market by Type
  1. 4.1 NK-1 Receptor Antagonists Type Introduction
  2. 4.1.1 Netupitant
  3. 4.1.2 Maropitant
  4. 4.1.3 Rolapitant
  5. 4.1.4 Fosaprepitant
  6. 4.1.5 Aprepitant
  7. 4.1.6 Other
  8. 4.2 Global NK-1 Receptor Antagonists Sales Volume by Type
  9. 4.2.1 Global NK-1 Receptor Antagonists Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global NK-1 Receptor Antagonists Sales Volume by Type (2021-2032)
  11. 4.2.3 Global NK-1 Receptor Antagonists Sales Volume Share by Type (2021-2032)
  12. 4.3 Global NK-1 Receptor Antagonists Sales Value by Type
  13. 4.3.1 Global NK-1 Receptor Antagonists Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global NK-1 Receptor Antagonists Sales Value by Type (2021-2032)
  15. 4.3.3 Global NK-1 Receptor Antagonists Sales Value Share by Type (2021-2032)
5 NK-1 Receptor Antagonists Market by Application
  1. 5.1 NK-1 Receptor Antagonists Application Introduction
  2. 5.1.1 Chemotherapy-induced Nausea and Vomiting (CINV)
  3. 5.1.2 Postoperative Nausea and Vomiting (PONV)
  4. 5.1.3 Other
  5. 5.2 Global NK-1 Receptor Antagonists Sales Volume by Application
  6. 5.2.1 Global NK-1 Receptor Antagonists Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global NK-1 Receptor Antagonists Sales Volume by Application (2021-2032)
  8. 5.2.3 Global NK-1 Receptor Antagonists Sales Volume Share by Application (2021-2032)
  9. 5.3 Global NK-1 Receptor Antagonists Sales Value by Application
  10. 5.3.1 Global NK-1 Receptor Antagonists Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global NK-1 Receptor Antagonists Sales Value by Application (2021-2032)
  12. 5.3.3 Global NK-1 Receptor Antagonists Sales Value Share by Application (2021-2032)
6 NK-1 Receptor Antagonists Regional Sales and Value Analysis
  1. 6.1 Global NK-1 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global NK-1 Receptor Antagonists Sales by Region (2021-2032)
  3. 6.2.1 Global NK-1 Receptor Antagonists Sales by Region: 2021-2026
  4. 6.2.2 Global NK-1 Receptor Antagonists Sales by Region (2027-2032)
  5. 6.3 Global NK-1 Receptor Antagonists Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global NK-1 Receptor Antagonists Sales Value by Region (2021-2032)
  7. 6.4.1 Global NK-1 Receptor Antagonists Sales Value by Region: 2021-2026
  8. 6.4.2 Global NK-1 Receptor Antagonists Sales Value by Region (2027-2032)
  9. 6.5 Global NK-1 Receptor Antagonists Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America NK-1 Receptor Antagonists Sales Value (2021-2032)
  12. 6.6.2 North America NK-1 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe NK-1 Receptor Antagonists Sales Value (2021-2032)
  15. 6.7.2 Europe NK-1 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific NK-1 Receptor Antagonists Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific NK-1 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America NK-1 Receptor Antagonists Sales Value (2021-2032)
  21. 6.9.2 South America NK-1 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa NK-1 Receptor Antagonists Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa NK-1 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
7 NK-1 Receptor Antagonists Country-level Sales and Value Analysis
  1. 7.1 Global NK-1 Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global NK-1 Receptor Antagonists Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global NK-1 Receptor Antagonists Sales by Country (2021-2032)
  4. 7.3.1 Global NK-1 Receptor Antagonists Sales by Country (2021-2026)
  5. 7.3.2 Global NK-1 Receptor Antagonists Sales by Country (2027-2032)
  6. 7.4 Global NK-1 Receptor Antagonists Sales Value by Country (2021-2032)
  7. 7.4.1 Global NK-1 Receptor Antagonists Sales Value by Country (2021-2026)
  8. 7.4.2 Global NK-1 Receptor Antagonists Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt NK-1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt NK-1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt NK-1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Dr. Reddy's Laboratories
  2. 8.1.1 Dr. Reddy's Laboratories Company Information
  3. 8.1.2 Dr. Reddy's Laboratories Business Overview
  4. 8.1.3 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolio
  6. 8.1.5 Dr. Reddy's Laboratories Recent Developments
  7. 8.2 Eugia Pharma
  8. 8.2.1 Eugia Pharma Company Information
  9. 8.2.2 Eugia Pharma Business Overview
  10. 8.2.3 Eugia Pharma NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eugia Pharma NK-1 Receptor Antagonists Product Portfolio
  12. 8.2.5 Eugia Pharma Recent Developments
  13. 8.3 Fresenius Kabi
  14. 8.3.1 Fresenius Kabi Company Information
  15. 8.3.2 Fresenius Kabi Business Overview
  16. 8.3.3 Fresenius Kabi NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Fresenius Kabi NK-1 Receptor Antagonists Product Portfolio
  18. 8.3.5 Fresenius Kabi Recent Developments
  19. 8.4 Glenmark
  20. 8.4.1 Glenmark Company Information
  21. 8.4.2 Glenmark Business Overview
  22. 8.4.3 Glenmark NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Glenmark NK-1 Receptor Antagonists Product Portfolio
  24. 8.4.5 Glenmark Recent Developments
  25. 8.5 Helsinn Healthcare
  26. 8.5.1 Helsinn Healthcare Company Information
  27. 8.5.2 Helsinn Healthcare Business Overview
  28. 8.5.3 Helsinn Healthcare NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolio
  30. 8.5.5 Helsinn Healthcare Recent Developments
  31. 8.6 Heron Therapeutics
  32. 8.6.1 Heron Therapeutics Company Information
  33. 8.6.2 Heron Therapeutics Business Overview
  34. 8.6.3 Heron Therapeutics NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Heron Therapeutics NK-1 Receptor Antagonists Product Portfolio
  36. 8.6.5 Heron Therapeutics Recent Developments
  37. 8.7 Lupin
  38. 8.7.1 Lupin Company Information
  39. 8.7.2 Lupin Business Overview
  40. 8.7.3 Lupin NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Lupin NK-1 Receptor Antagonists Product Portfolio
  42. 8.7.5 Lupin Recent Developments
  43. 8.8 MSN
  44. 8.8.1 MSN Company Information
  45. 8.8.2 MSN Business Overview
  46. 8.8.3 MSN NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 MSN NK-1 Receptor Antagonists Product Portfolio
  48. 8.8.5 MSN Recent Developments
  49. 8.9 Mylan
  50. 8.9.1 Mylan Company Information
  51. 8.9.2 Mylan Business Overview
  52. 8.9.3 Mylan NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Mylan NK-1 Receptor Antagonists Product Portfolio
  54. 8.9.5 Mylan Recent Developments
  55. 8.10 Steriscience
  56. 8.10.1 Steriscience Company Information
  57. 8.10.2 Steriscience Business Overview
  58. 8.10.3 Steriscience NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Steriscience NK-1 Receptor Antagonists Product Portfolio
  60. 8.10.5 Steriscience Recent Developments
  61. 8.11 TerSera Therapeutics
  62. 8.11.1 TerSera Therapeutics Company Information
  63. 8.11.2 TerSera Therapeutics Business Overview
  64. 8.11.3 TerSera Therapeutics NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolio
  66. 8.11.5 TerSera Therapeutics Recent Developments
  67. 8.12 Teva
  68. 8.12.1 Teva Company Information
  69. 8.12.2 Teva Business Overview
  70. 8.12.3 Teva NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Teva NK-1 Receptor Antagonists Product Portfolio
  72. 8.12.5 Teva Recent Developments
  73. 8.13 Torrent Pharmaceuticals
  74. 8.13.1 Torrent Pharmaceuticals Company Information
  75. 8.13.2 Torrent Pharmaceuticals Business Overview
  76. 8.13.3 Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolio
  78. 8.13.5 Torrent Pharmaceuticals Recent Developments
  79. 8.14 Beijing Sihuan Pharmaceutical
  80. 8.14.1 Beijing Sihuan Pharmaceutical Company Information
  81. 8.14.2 Beijing Sihuan Pharmaceutical Business Overview
  82. 8.14.3 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  84. 8.14.5 Beijing Sihuan Pharmaceutical Recent Developments
  85. 8.15 Hansoh Pharma
  86. 8.15.1 Hansoh Pharma Company Information
  87. 8.15.2 Hansoh Pharma Business Overview
  88. 8.15.3 Hansoh Pharma NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Hansoh Pharma NK-1 Receptor Antagonists Product Portfolio
  90. 8.15.5 Hansoh Pharma Recent Developments
  91. 8.16 Merck
  92. 8.16.1 Merck Company Information
  93. 8.16.2 Merck Business Overview
  94. 8.16.3 Merck NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Merck NK-1 Receptor Antagonists Product Portfolio
  96. 8.16.5 Merck Recent Developments
  97. 8.17 Qilu Pharmaceutical
  98. 8.17.1 Qilu Pharmaceutical Company Information
  99. 8.17.2 Qilu Pharmaceutical Business Overview
  100. 8.17.3 Qilu Pharmaceutical NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  102. 8.17.5 Qilu Pharmaceutical Recent Developments
  103. 8.18 Sandoz
  104. 8.18.1 Sandoz Company Information
  105. 8.18.2 Sandoz Business Overview
  106. 8.18.3 Sandoz NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Sandoz NK-1 Receptor Antagonists Product Portfolio
  108. 8.18.5 Sandoz Recent Developments
  109. 8.19 Yichang Humanwell Pharmaceutical
  110. 8.19.1 Yichang Humanwell Pharmaceutical Company Information
  111. 8.19.2 Yichang Humanwell Pharmaceutical Business Overview
  112. 8.19.3 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  114. 8.19.5 Yichang Humanwell Pharmaceutical Recent Developments
  115. 8.20 Chia Tai Tianqing Pharmaceutical
  116. 8.20.1 Chia Tai Tianqing Pharmaceutical Company Information
  117. 8.20.2 Chia Tai Tianqing Pharmaceutical Business Overview
  118. 8.20.3 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
  120. 8.20.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 NK-1 Receptor Antagonists Value Chain Analysis
  2. 9.1.1 NK-1 Receptor Antagonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 NK-1 Receptor Antagonists Sales Mode & Process
  6. 9.2 NK-1 Receptor Antagonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 NK-1 Receptor Antagonists Distributors
  9. 9.2.3 NK-1 Receptor Antagonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst